(R)-N-(tert-butoxycarbonyl)-α-(dimethylaminomethyl)benzylamine | 224633-14-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (R)-N-(tert-butoxycarbonyl)-α-(dimethylaminomethyl)benzylamine
• 英文别名: (R)-(2-(dimethylamino)-1-phenylethyl)carbamic acid tert-butyl ester；[(1R)-2-(Dimethylamino)-1-phenylethyl]carbamic acid 1,1-dimethylethyl ester；tert-butyl N-[(1R)-2-(dimethylamino)-1-phenylethyl]carbamate
• CAS: 224633-14-1
• 化学式: C₁₅H₂₄N₂O₂
• 分子量: 264.368
• InChiKey: MXXPLUXJHWXFIP-ZDUSSCGKSA-N

物化性质

• 沸点：
  377.9±42.0 °C(Predicted)
• 密度：
  1.024±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (R)-N-(tert-butoxycarbonyl)-α-(dimethylaminomethyl)benzylamine 在 sodium cyanoborohydride 、 溶剂黄146 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 5.0h， 生成 (1R)-N',N'-dimethyl-1-phenyl-N-[1-[3-[5-(1,2,4-triazol-4-yl)-1H-indol-3-yl]propyl]piperidin-4-yl]ethane-1,2-diamine
  参考文献：
  名称：

  3- [3-（Piperidin-1-yl）propyl]吲哚作为高选择性h5-HT（1D）受体激动剂。

  摘要：

  几种5-HT（1D / 1B）受体激动剂目前正作为偏头痛的治疗方法进入市场。本文介绍了选择性的h5-HT（1D）受体激动剂作为潜在的偏头痛药物的发展，它可能产生较少的副作用。合成了一系列3- [3-（哌啶-1-基）丙基]吲哚，该化合物导致鉴定出80（L-772,405），这是一种具有170的高亲和力h5-HT（1D）受体全激动剂对h5-HT（1D）受体的选择性是h5-HT（1B）受体的两倍。L-772,405在一系列其他5-羟色胺和非5-羟色胺受体上也表现出非常好的选择性，并且在大鼠皮下给药后具有出色的生物利用度。因此，它构成了描述偏头痛中h5-HT（1D）受体作用的有价值的工具。

  DOI：

  10.1021/jm9910021
• 作为产物：
  描述：

  D-苯甘氨醇 在 TEA 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 5.5h， 生成 (R)-N-(tert-butoxycarbonyl)-α-(dimethylaminomethyl)benzylamine
  参考文献：
  名称：

  Discovery of a Novel Class of Selective Non-Peptide Antagonists for the Human Neurokinin-3 Receptor. 2. Identification of (S)-N-(1-Phenylpropyl)-3-hydroxy-2- phenylquinoline-4-carboxamide (SB 223412)

  摘要：

  Optimization of the previously reported 2-phenyl-4-quinolinecarboxamide NK-3 receptor antagonist 14, with regard to potential metabolic instability of the ester moiety and affinity and selectivity for the human neurokinin-3 (hNK-3) receptor, is described. The ester functionality could be successfully replaced by the ketone (31) or by lower alkyl groups (Et, 21, or n-Pr, 24). Investigation of the substitution pattern of the quinoline ring resulted in the identification of position 3 as a key position to enhance hNK-3 binding affinity and selectivity for the hNK-3 versus the hNK-2 receptor. All of the chemical groups introduced at this position, with the exception of halogens, increased the hNK-3 binding affinity, and compounds 53 (3-OH, SE 223412, hNK-3-CHO binding K-i = 1.4 nM) and 55 (3-NHz, hNK-3-CHO binding K-i = 1.2 nM) were the most potent compounds of this series. Selectivity studies versus the other neurokinin receptors (hNK-8-CHO and hNK-1-CHO) revealed that 53 is about 100-fold selective for the hNK-3 versus hNK-2 receptor, with no affinity for the hNK-1 at concentrations up to 100 mu M. In vitro studies demonstrated that 53 is a potent functional antagonist of the hNK-3 receptor (reversal of senktide-induced contractions in rabbit isolated iris sphincter muscles and reversal of NKB-induced Ca2+ mobilization in CHO cells stably expressing the hNK-3 receptor), while in vivo this compound showed oral and intravenous activity in NK-3 receptor-driven models (senktide-induced behavioral responses in mice and senktide-induced miosis in rabbits). Overall, the biological data indicate that (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (53, SE 223412) may serve as a pharmacological tool in animal models of disease to assess the functional and pathophysiological role of the NK-3 receptor and to establish therapeutic indications for non-peptide NK-3 receptor antagonists.

  DOI：

  10.1021/jm980633c

文献信息

• Discovery of a Novel Class of Selective Non-Peptide Antagonists for the Human Neurokinin-3 Receptor. 2. Identification of (<i>S</i>)-<i>N</i>-(1-Phenylpropyl)-3-hydroxy-2- phenylquinoline-4-carboxamide (SB 223412)
  作者：Giuseppe A. M. Giardina、Luca F. Raveglia、Mario Grugni、Henry M. Sarau、Carlo Farina、Andrew D. Medhurst、Davide Graziani、Dulcie B. Schmidt、Roberto Rigolio、Mark Luttmann、Stefano Cavagnera、James J. Foley、Vittorio Vecchietti、Douglas W. P. Hay

  DOI：10.1021/jm980633c

  日期：1999.3.1

  Optimization of the previously reported 2-phenyl-4-quinolinecarboxamide NK-3 receptor antagonist 14, with regard to potential metabolic instability of the ester moiety and affinity and selectivity for the human neurokinin-3 (hNK-3) receptor, is described. The ester functionality could be successfully replaced by the ketone (31) or by lower alkyl groups (Et, 21, or n-Pr, 24). Investigation of the substitution pattern of the quinoline ring resulted in the identification of position 3 as a key position to enhance hNK-3 binding affinity and selectivity for the hNK-3 versus the hNK-2 receptor. All of the chemical groups introduced at this position, with the exception of halogens, increased the hNK-3 binding affinity, and compounds 53 (3-OH, SE 223412, hNK-3-CHO binding K-i = 1.4 nM) and 55 (3-NHz, hNK-3-CHO binding K-i = 1.2 nM) were the most potent compounds of this series. Selectivity studies versus the other neurokinin receptors (hNK-8-CHO and hNK-1-CHO) revealed that 53 is about 100-fold selective for the hNK-3 versus hNK-2 receptor, with no affinity for the hNK-1 at concentrations up to 100 mu M. In vitro studies demonstrated that 53 is a potent functional antagonist of the hNK-3 receptor (reversal of senktide-induced contractions in rabbit isolated iris sphincter muscles and reversal of NKB-induced Ca2+ mobilization in CHO cells stably expressing the hNK-3 receptor), while in vivo this compound showed oral and intravenous activity in NK-3 receptor-driven models (senktide-induced behavioral responses in mice and senktide-induced miosis in rabbits). Overall, the biological data indicate that (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (53, SE 223412) may serve as a pharmacological tool in animal models of disease to assess the functional and pathophysiological role of the NK-3 receptor and to establish therapeutic indications for non-peptide NK-3 receptor antagonists.
• 3-[3-(Piperidin-1-yl)propyl]indoles as Highly Selective h5-HT_1D Receptor Agonists
  作者：Michael G. N. Russell、Victor G. Matassa、Roy R. Pengilley、Monique B. van Niel、Bindi Sohal、Alan P. Watt、Laure Hitzel、Margaret S. Beer、Josephine A. Stanton、Howard B. Broughton、José L. Castro

  DOI：10.1021/jm9910021

  日期：1999.12.2

  5-HT(1D/1B) receptor agonists are now entering the marketplace as treatments for migraine. This paper describes the development of selective h5-HT(1D) receptor agonists as potential antimigraine agents which may produce fewer side effects. A series of 3-[3-(piperidin-1-yl)propyl]indoles has been synthesized which has led to the identification of 80 (L-772,405), a high-affinity h5-HT(1D) receptor full agonist

  几种5-HT（1D / 1B）受体激动剂目前正作为偏头痛的治疗方法进入市场。本文介绍了选择性的h5-HT（1D）受体激动剂作为潜在的偏头痛药物的发展，它可能产生较少的副作用。合成了一系列3- [3-（哌啶-1-基）丙基]吲哚，该化合物导致鉴定出80（L-772,405），这是一种具有170的高亲和力h5-HT（1D）受体全激动剂对h5-HT（1D）受体的选择性是h5-HT（1B）受体的两倍。L-772,405在一系列其他5-羟色胺和非5-羟色胺受体上也表现出非常好的选择性，并且在大鼠皮下给药后具有出色的生物利用度。因此，它构成了描述偏头痛中h5-HT（1D）受体作用的有价值的工具。